StrandDx™-ASD is based on novel molecular biomarkers developed using LinusBio’s proprietary exposome and biological response sequencing platform, utilizing a single strand of hair. The intended use of StrandDx™-ASD will extend to patients from birth to 21 years.

The FDA has awarded breakthrough designation to StrandDx-ASD, and we are working closely with the FDA for full approval in the United States.

Please complete this form to sign up for updates on the development and availability of StrandDx-ASD diagnostic aid.

---

For Health Care Professionals 

---

For the Autism Community